Lanzamiento Enero 2027

Ensayo controlado aleatorizado1992Financiación no declarada

Renal elimination of magnesium as a parameter of bioavailability of oral magnesium therapy

Kuhn I, Jost V, Wieckhorst G, Theiss U, Lücker PW

Methods and findings in experimental and clinical pharmacology · 3 citas

Etiquetas de revisión

Financiación no declarada

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño
Ensayo controlado aleatorizado (indexado por PubMed)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento

Quién lo pagó

Financiación
Financiación no declarada

Publicación

Publicado
1992-05-01 · Methods Find Exp Clin Pharmacol · vol. 14 · número 4 · págs. 269–72
Editorial
National Institutes of Health
Citado
9 citas · más que el 30% de estudios similares · 0.0× el promedio de su campo
Referencias
0 trabajos
Acceso
De pago
Áreas de investigación
Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Drug Solubulity and Delivery Systems
Palabras clave
magnesium bioavailability, hypomagnesemia
MeSH
kidney, humans, magnesium, administration, oral, biological availability, adult, male

5 autores

  • I Kuhn
  • V Jost
  • G. Wieckhorst
  • Ursula Theiss
  • Peter Wolfgang Lücker

Resumen

El texto original del estudio, en el idioma en que se publicó.

Magnesium is an important cation in human physiology, especially in the regulation of membrane proteins, as a cofactor for various enzyme systems and in neuromuscular transmission. Magnesium deficiency leads to severe impairment in muscle function, particularly in cardiovascular diseases. Classical bioavailability studies with magnesium cannot be carried out for several reasons. As the magnesium concentration in plasma is extraordinarily well regulated, renal elimination proves to be the best method to determine the absorption of orally administered magnesium. Magnesium pools must first be filled, and the saturation phase of renal elimination then equals the degree of absorption. This parameter of bioavailability shows the percentage of eliminated magnesium in comparison to the administered dose. Eighteen healthy male volunteers were included in this study to compare 5 mg magnesium-DL-hydrogen aspartate with magnesium-L-hydrogen aspartate. After a saturation phase, the test substances were administered in random order. Blood samples for determination of magnesium concentrations were taken, but no typical pharmacokinetic concentration curves were obtained. The areas under the concentration-time curves were equal for both formulations (x = 40.22 [mval*h/l]). The bioavailability of both substances was determined from the renal elimination. No significant difference was found between both treatments. Bioavailability of 5 mg magnesium-DL-hydrogen aspartate was 44.5% and for magnesium-L-hydrogen aspartate 41.7%. It is evident that this method of magnesium determination is practical, comfortable for volunteers and gives reliable results in comparing the absorption of magnesium formulations.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.